Louisiana Administrative Code
Title 33 - ENVIRONMENTAL QUALITY
Part XV - Radiation Protection
Chapter 7 - Use of Radionuclides in the Healing Arts
Section XV-735 - Use of Radiopharmaceuticals for Therapy

Universal Citation: LA Admin Code XV-735

Current through Register Vol. 50, No. 9, September 20, 2024

A. A licensee may use the following prepared radiopharmaceuticals:

1. iodine-131 as iodide for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma;

2. phosphorus-32 as soluble phosphate for treatment of polycythemia vera, leukemia, and bone metastases;

3. phosphorus-32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions;

4. any radioactive material in a radiopharmaceutical and for a therapeutic use for which the Food and Drug Administration has accepted a "Notice of Claimed Investigational Exemption for a New Drug" (IND), or approved a "New Drug Application" (NDA). The licensee shall comply with the package insert instructions regarding indications and method of administration.

B. The radiopharmaceuticals specified in Subsection A of this Section shall be either:

1. obtained from a manufacturer, preparer, or a PET radioactive drug producer, licensed in accordance with LAC 33:XV.328.J or equivalent Nuclear Regulatory Commission or agreement state requirements; or

2. prepared by an authorized nuclear pharmacist, a physician who is an authorized user and who meets the requirements specified in LAC 33:XV.763.C, or an individual under the supervision of either as specified in LAC 33:XV.709.

C. A licensee may use any unsealed byproduct material identified in 763.E.1.b.i.(b).(vii) prepared for medical use and for which a written directive is required that is:

1. obtained from:
a. a manufacturer or preparer licensed under LAC 33:XV.328.J or equivalent agreement state requirements; or

b. a PET radioactive drug producer licensed in accordance with LAC 33:XV.324.D.1 or equivalent NRC or agreement state requirements; or

2. excluding production of PET radionuclides, prepared by:
a. an authorized nuclear pharmacist;

b. a physician who is an authorized user and who meets the requirements specified in LAC 33:XV.763.D or E.1; or

c. an individual under the supervision, as specified in LAC 33:XV.709, of the authorized nuclear pharmacist in Subparagraph C.2.a of this Section or the physician who is an authorized user in Subparagraph C.2.b of this Section; or

3. obtained from and prepared by a NRC or agreement state licensee, for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA; or

4. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 30:2001 et seq. and 2104.B.

Disclaimer: These regulations may not be the most recent version. Louisiana may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.